What class action lawsuit settlement options exist from the side effects of dosage of Risperdal medication in Davenport VA| Risperdal consta for depression, anxiety, bi-polar disorder and children in Virginia

[ssad ssadblk=”alta white”]  It is very possible there is a doctor in Davenport VA who has written a script for Risperdal, just as there has been throught the country.

The Risperdal lawsuits list a number of of side effects, including breast development in males, an increased risk of diabetes, heart disease and floppy iris syndrome for patients undergoing cataract surgery.  Since the drug usage is for patients young and old, people young and old have experienced some of these side effects in different aspects.

In additional to these risks in adults, some children have been reported to experience some of these side effects. Some recent reports found that antipsychotic drugs similar to Risperdal are becoming increasingly popular as more doctors are prescribing them for off-label use.

[weather city=”Davenport” state=”Virginia”]

If you or any of your family or friends has suffered harm from the use of Risperdal, you should find an experienced attorney who will be able to discern if there are grounds to file a lawsuit against J&J. For more information fill out the form below to see if we can help you.

[google-map location=”Davenport VA”]

 

J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts

 

[ssad ssadblk=”pain relief”]

 

Opening arguments made as case gets under way in Philadelphia

January 26, 2015 | By Eric Palmer

Johnson & Johnson ($JNJ) some time back agreed to pay $2.2 billion to settle federal claims that it improperly marketed the antipsychotic drug Risperdal. But the drugmaker’s legal hassles over the drug are not all done. Last week opening arguments were made in a case in which the drugmaker is accused of marketing the drug for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts.
In their opening arguments, lawyers for J&J’sJanssen countered that the FDA-approved label for the drug was sufficient because it lists the possibility of elevated levels of the hormone that can cause gynecomastia, the name for the condition.The case in the Philadelphia Court of Common Pleas revolves around a young man, now 20, that suffered that side effect, a condition his lawyers said in opening statements can only be dealt with through a mastectomy. According to a description of the opening arguments from Sheller, the law firm that brought the case, they contend their client was prescribed Risperdal “off label” at age 8. Former FDA Commissioner David Kessler is slated to testify in the case. He was brought to testify in some earlier cases but J&J then settled before they reached that point.

The drug, which went off patent in 2007, was a big seller for J&J. In the 7 years between 2003 to 2010, Risperdal brought in more than $24 billion worldwide. But the legal fallout from its off-label use has been costly to the drugmaker. In addition to the $2.2 billion settlement J&J made in the federal whistleblower lawsuit, it also settled off-label marketing claims with 36 states and the District of Columbia over the marketing of Risperdal that topped $180 million–then with Texas for $158 million more.

But it has also successfully fought off some verdicts. J&J lost a $1.2 billion verdict in Arkansas over similar claims but that mammoth award was killed last year when the Arkansas Supreme Court ruled that the state had filed the case under a statute that applied to healthcare companies but not pharma companies. J&J also deflected a $257 million award in Louisiana after convincing the supreme court in that state that its marketing had not violated a state law.

 

Instant SEO Plan
Rank On Page 1 of Google instantly.
45 E. City Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: (484) 881-3267

 

 

Find an attorney that handles Xarelto class action lawsuits in Ridgeview SD | Lawyers who makes claims settlements and litigation from Xarelto blood thinner in South Dakota

[ssad ssadblk=”diabetes”]

Blood thinner drug Xarelto, although having issues, continues to grow in sales.

 Pharmaceutical powerhouses Bayer and Johnson & Johnson face the first lawsuits related to safety concerns for the billion-dollar blood thinner Xarelto, according to Reuters.

Plaintiffs submitted claims following severe internal bleeding sent them to the hospital. In those cases, patients took Xarelto (rivaroxaban), and their claims blame the excessive bleeding on that use.

Unlike warfarin, a trusted mainstay for preventing blood clots for the past 50 years, Xarelto does not have an antidote to stop uncontrolled bleeding, which can be fatal.

A patient from Kentucky Virginia Stunteneck filed a lawsuit against Bayer in the U.S. District Court of the Eastern District of Pennsylvania. Stunteneck was hospitalized after was given Xarelto and suffered severe internal bleeding in 2013.

She asserts the drug should not be sold and that Bayer and J&Jcontinued to sell it even if they were aware of the risks. The companies also did not inform the public.

 

“As the manufacturers and distributors of Xarelto, defendants knew or should have known that Xarelto use was associated with irreversible bleeds,” Stunteneck’s complaint said.

In May, Boehringer Ingelheim paid $650 million to settle thousands of internal bleeding cases involving its blood thinner, Pradaxa. The drug hit the market in 2010, a year before Xarelto. Both drugs share the same bleeding side effects.

Attorneys say they expect more claims after the general public becomes more aware of the potential hazards of the drug.  If you took Xarelto and had internal bleeding or a pulmonary embolism, you may have legal options.

[ssad ssadblk=”National Debt 3″]

 

GET HELP NOW

FDA Rejects Xarelto for Acute Coronary Syndrome

This initial group of claims comes a few months after the U.S. Food and Drug Administration’s (FDA) advisory panel gave Xarelto a unanimous refusal for approval as a treatment for patients with sudden reduced blood flow to the heart, including heart attacks and chest pain, also known as acute coronary syndrome (ACS).

While the drug is approved for a number of uses, adding acceptance for ACS would grant Xarelto access to over 1.1 million Americans who are sent to the hospital each year with the condition.

The panel decision was a third strike for Bayer and J&J for FDA approval.

The panel voted that the drug should be denied usage to prevent new heart attacks and stroke in patients with ACS because it lacked sufficient  clinical data to support the approval. The experts also indicated that some trial data was actually missing.

“We appreciate the thoroughness of the committee’s review and continue to believe rivaroxaban, in addition to the current standard of care, may help provide patients with ACS additional protection against life-threatening cardiovascular events such as death, heart attack and stroke,” Paul Burton, VP of clinical development for J&J’s Janssen R&D segment said in a statement.

Xarelto Expected to Increase Sales

Despite the fact that the drug companies have legal issues about another drug that has a questional safety profile, Xarelto sales seems strong, and partners Bayer and J&J are making substantial profits. In the first year of the drug’s sales, Bayer generated about $431 million in Europe. J&J earned $239 million in U.S. sales.

Sales in both large markets continue to florish.

The drug is experiencing a similar history of its predecessor, Boehringer Ingelheim’s Pradaxa, another drug that has robust sales. Even though the risk of internal bleeding concerned doctors, it was still being prescribed by these doctors.

Xarelto is currently approved for more uses than Pradaxa.

Bayer and J&J continue to pursue FDA approval despite being shut down for ACS treatment. The companies are investigating whether or not the drug can be used in combination with aspirin to stop heart attacks, death and stroke. In addition, the companies plan to start testing Xarelto on patients with chronic artery disease and heart failure.

By 2018, analysts say Xarelto will generate about $3.68 billion in annual sales.

Why File a Xarelto Lawsuit?

 Approved in 2011, Xarelto (rivaroxaban) is one of the newest blood thinners on the market and is manufactured by Bayer and marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, in the United States. The most dangerous side effect for people taking Xarelto is uncontrollable bleeding �” a risk shared by all blood thinners. Some of the country’s top heart doctors are concerned about Xarelto’s safety.

  • Financial suffering caused by emergency visits, long term care, and lost wages due to time away from work.
  • Emotional pain and suffering from caring for loved ones experiencing medical problems
  • The burden of funeral expenses because of death as a result of uncontrolled bleeding caused by Xarelto.
  • Holding Bayer and Janssen Pharmaceuticals accountable for releasing a dangerous drug. Internal Bleeding

Multidistrict Litigation (MDL)

[weather city=”Ridgeview” state=”South Dakota”]

Because of the large number of lawsuits filed, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into multidistrict litigation (MDL). An MDL helps simplify the process because groups of cases can be handled by the same experienced judge and in the same court. People whose lawsuits are included in an MDL keep their own lawyers, and their suits are still handled as individual cases.

Where’s the exit strategy?
There is no such option for Xarelto. When a Xarelto Bleedout starts, there are so few options to stop it.

The result can many times lead to Xarelto Death.

Manufacturers of Xarelto and its competitors are hoping to find an antidote after the fact. In the meantime, manufacturers are continuing to spend big dollars on new anticoagulants such as Xarelto, extolling the benefits of their effectiveness and convenience.

[google-map location=”Ridgeview SD”]

Instant SEO Plan
Rank on Page 1 of Google INSTANTLY!
45 E. Cityline Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: 484-881-3267

Find an attorney that handles Xarelto class action lawsuits in Pearl MS | Lawyers who makes claims settlements and litigation from Xarelto blood thinner in Mississippi

[ssad ssadblk=”diabetes”]

Blood thinner drug Xarelto, although having issues, continues to grow in sales.

 Pharmaceutical powerhouses Bayer and Johnson & Johnson face the first lawsuits in response to safety concerns for the billion-dollar blood thinner Xarelto, according to Reuters.

Plaintiffs filed claims after severe internal bleeding sent them to the hospital. In those cases, patients took Xarelto (rivaroxaban), and their claims blame the severe uncontrollable bleeding on that use.

Unlike warfarin, a trusted mainstay for preventing blood clots for the past 50 years, Xarelto has yet to have an antidote to stop uncontrolled bleeding, which can be fatal.

A patient from Kentucky Virginia Stunteneck filed a lawsuit against Bayer in the U.S. District Court of the Eastern District of Pennsylvania. Stunteneck was hospitalized after was given Xarelto and endured severe gastrointestinal bleeding in 2013.

She asserts the drug should not be sold and that Bayer and J&Jcontinued to keep it on the market even if they were aware of the risks. The companies also did not disclose it to the public.

 

“As the manufacturers and distributors of Xarelto, defendants knew or should have known that Xarelto use was associated with irreversible bleeds,” Stunteneck’s complaint said.

In May, Boehringer Ingelheim paid $650 million to settle thousands of internal bleeding cases involving its blood thinner, Pradaxa. The drug hit the market in 2010, a year before Xarelto. Both drugs share the same bleeding side effects.

Attorneys say they expect more claims after more people become aware of the dangers of the drug.  If you took Xarelto and had internal bleeding or a pulmonary embolism, you may have legal options.

[ssad ssadblk=”National Debt 1″]

 

GET HELP NOW

FDA Rejects Xarelto for Acute Coronary Syndrome

This first wave of claims comes a few months after the U.S. Food and Drug Administration’s (FDA) advisory panel gave Xarelto a unanimous refusal for approval as a maintenance drug for patients with sudden reduced blood flow to the heart, including heart attacks and chest pain, also known as acute coronary syndrome (ACS).

While the drug is approved for a number of uses, adding approval for ACS would grant Xarelto access to over 1.1 million Americans who find themselves going to the hospital each year with the condition.

The panel decision was a third strike for Bayer and J&J for FDA approval.

The panel voted that the drug should be denied usage to prevent new heart attacks and stroke in patients with ACS because it lacked sufficient  clinical data to support the approval. The experts also indicated that some trial data was actually missing.

“We appreciate the thoroughness of the committee’s review and continue to believe rivaroxaban, in addition to the current standard of care, may help provide patients with ACS additional protection against life-threatening cardiovascular events such as death, heart attack and stroke,” Paul Burton, VP of clinical development for J&J’s Janssen R&D segment said in a statement.

Xarelto Expected to Increase Sales

Despite the fact that the drug companies face litigation about another drug that has a controversial safety profile, Xarelto sales appears to be strong, and partners Bayer and J&J are making healthy profits. In the first year of the drug’s sales, Bayer generated about $431 million in Europe. J&J earned $239 million in U.S. sales.

Sales in both large markets continue to florish.

The drug follows in the footsteps of its predecessor, Boehringer Ingelheim’s Pradaxa, another drug that has vigourous sales. Even though the risk of internal bleeding concerned doctors, it was still being prescribed by these doctors.

Xarelto is currently approved for more uses than Pradaxa.

Bayer and J&J continue to pursue FDA approval regardless of being shut down for ACS treatment. The companies are investigating whether or not the drug can be used in combination with aspirin to stop heart attacks, death and stroke. In addition, the companies plan to start tests of Xarelto on patients with chronic artery disease and heart failure.

By 2018, analysts say Xarelto will generate about $3.68 billion in annual sales.

Why File a Xarelto Lawsuit?

 Approved in 2011, Xarelto (rivaroxaban) is one of the newest blood thinners on the market and is manufactured by Bayer and marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, in the United States. The most damaging side effect for people taking Xarelto is continuous sustained bleeding �” a risk shared by all blood thinners. Some of the country’s top heart doctors are worried about Xarelto’s safety.

  • Financial suffering caused by emergency visits, ongoing care, and lost wages due to time away from work.
  • Emotional distress from taking care of loved ones experiencing medical problems
  • The burden of unexpected final expenses because of death as a result of uncontrolled bleeding caused by Xarelto.
  • Holding Bayer and Janssen Pharmaceuticals accountable for releasing a dangerous drug. Internal Bleeding

Multidistrict Litigation (MDL)

[weather city=”Pearl” state=”Mississippi”]

Because of the volume of lawsuits filed, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into multidistrict litigation (MDL). An MDL helps simplify the process because groups of cases can be handled by the same knowledgeable judge and in the same court. People whose lawsuits are included in an MDL keep their own lawyers, and their suits are still handled [ndividually.

Where’s the exit strategy?
There is no such option for Xarelto. When a Xarelto Bleedout starts, there are so few options to stop it.

The result can often lead to Xarelto Death.

Makers of Xarelto and its competitors are hoping to find an antidote after the fact. In the meantime, manufacturers are continuing to allocate huge budgets on new anticoagulants such as Xarelto, touting their efficacy and convenience.

[google-map location=”Pearl MS”]

Instant SEO Plan
Rank on Page 1 of Google INSTANTLY!
45 E. Cityline Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: 484-881-3267

What class action lawsuit settlement options exist from the side effects of dosage of Risperdal medication in Valley Fork WV| Risperdal consta for depression, anxiety, bi-polar disorder and children in West Virginia

[ssad ssadblk=”health plan “])

Risperdal doing more harm than good.

 

Risperdal is an antipsychotic medication prescribed to patients with mental illness and a host of other mental behavior issues.  The use of this drug has made it difficult for some people.

Risperdal was first approved by the FDA in 1993 for the treatment of schizophrenia in adults. But since then, hundreds of lawsuits have been filed against the drug’s manufacturer, Johnson and Johnson, due to Risperdal side effects.  Cases have popped up across the country as the drug has been widely distributed  It is very possible there is a doctor in Valley Fork WV who has issued a prescription for Risperdal, just as there has been throught the country.

The Risperdal lawsuits list a number of of side effects, including breast development in men, an increased risk of diabetes, heart disease and floppy iris syndrome for patients having cataract surgery.  Since the drug usage is for patients of all ages, people young and old have suffered through some of these side effects in different aspects.

In additional to these risks in adults, some children have been reported to experience some of these side effects. Some recent reports found that antipsychotic drugs like Risperdal are becoming increasingly popular as there has been an increase in doctors writing prescriptions to use them for off-label use.

[weather city=”Valley Fork” state=”West Virginia”]

If you or any of your family or friends has suffered harm from Risperdal, you should find an experienced attorney who can determine if you may have a case against J&J. For more information provide us with your contact information in the form below to see if we can help you.

[google-map location=”Valley Fork WV”]

 

J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts

 

[ssad ssadblk=”pain relief”]

 

Opening arguments made as case gets under way in Philadelphia

January 26, 2015 | By Eric Palmer

Johnson & Johnson ($JNJ) some time back agreed to pay $2.2 billion to settle federal claims that it improperly marketed the antipsychotic drug Risperdal. But the drugmaker’s legal hassles over the drug are not all done. Last week opening arguments were made in a case in which the drugmaker is accused of marketing the drug for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts.
In their opening arguments, lawyers for J&J’sJanssen countered that the FDA-approved label for the drug was sufficient because it lists the possibility of elevated levels of the hormone that can cause gynecomastia, the name for the condition.The case in the Philadelphia Court of Common Pleas revolves around a young man, now 20, that suffered that side effect, a condition his lawyers said in opening statements can only be dealt with through a mastectomy. According to a description of the opening arguments from Sheller, the law firm that brought the case, they contend their client was prescribed Risperdal “off label” at age 8. Former FDA Commissioner David Kessler is slated to testify in the case. He was brought to testify in some earlier cases but J&J then settled before they reached that point.

The drug, which went off patent in 2007, was a big seller for J&J. In the 7 years between 2003 to 2010, Risperdal brought in more than $24 billion worldwide. But the legal fallout from its off-label use has been costly to the drugmaker. In addition to the $2.2 billion settlement J&J made in the federal whistleblower lawsuit, it also settled off-label marketing claims with 36 states and the District of Columbia over the marketing of Risperdal that topped $180 million–then with Texas for $158 million more.

But it has also successfully fought off some verdicts. J&J lost a $1.2 billion verdict in Arkansas over similar claims but that mammoth award was killed last year when the Arkansas Supreme Court ruled that the state had filed the case under a statute that applied to healthcare companies but not pharma companies. J&J also deflected a $257 million award in Louisiana after convincing the supreme court in that state that its marketing had not violated a state law.

 

Instant SEO Plan
Rank On Page 1 of Google instantly.
45 E. City Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: (484) 881-3267

 

 

Find an attorney that handles Xarelto class action lawsuits in Streator IL | Lawyers who makes claims settlements and litigation from Xarelto blood thinner in Illinois

[ssad ssadblk=”diabetes”]

Blood thinner drug Xarelto, although having issues, continues to grow in sales.

 Drug giants Bayer and Johnson & Johnson face the first lawsuits in response to safety concerns for the billion-dollar blood thinner Xarelto, according to Reuters.

Plaintiffs submitted claims following severe internal bleeding sent them to the hospital. In those cases, patients took Xarelto (rivaroxaban), and their claims blame the severe uncontrollable bleeding on that use.

Unlike warfarin, a trusted mainstay for preventing blood clots for the past 50 years, Xarelto has yet to have an antidote to stop uncontrolled bleeding, which can be fatal.

A patient from Kentucky Virginia Stunteneck filed a lawsuit against Bayer in the U.S. District Court of the Eastern District of Pennsylvania. Stunteneck was hospitalized after was given Xarelto and endured severe gastrointestinal bleeding in 2013.

She asserts the drug should be recalled and that J&J and Bayercontinued to keep it on the market even if they were aware of the risks. The companies also did not inform the public.

 

“As the manufacturers and distributors of Xarelto, defendants knew or should have known that Xarelto use was associated with irreversible bleeds,” Stunteneck’s complaint said.

In May, Boehringer Ingelheim paid $650 million to settle thousands of internal bleeding cases involving its blood thinner, Pradaxa. The drug hit the market in 2010, a year before Xarelto. Both drugs share the same bleeding side effects.

Attorneys say they expect more lawsuits after more people become aware of the potential hazards of the drug.  If you took Xarelto and had internal bleeding or a pulmonary embolism, you may have legal options.

[ssad ssadblk=”identity force2″]

 

GET HELP NOW

FDA Rejects Xarelto for Acute Coronary Syndrome

This first wave of claims comes a few months after the U.S. Food and Drug Administration’s (FDA) advisory panel gave Xarelto a unanimous refusal for approval as a treatment for patients with sudden reduced blood flow to the heart, including heart attacks and chest pain, also known as acute coronary syndrome (ACS).

While the drug is approved for a numerous conditions, adding acceptance for ACS would grant Xarelto access to over 1.1 million Americans who are sent to the hospital each year with the condition.

The panel decision was a another blow for Bayer and J&J for FDA approval.

The panel voted that the drug should be denied usage to prevent new heart attacks and stroke in patients with ACS because there was not enough  clinical data to support the approval. The experts also indicated that some trial data was actually missing.

“We appreciate the thoroughness of the committee’s review and continue to believe rivaroxaban, in addition to the current standard of care, may help provide patients with ACS additional protection against life-threatening cardiovascular events such as death, heart attack and stroke,” Paul Burton, VP of clinical development for J&J’s Janssen R&D segment said in a statement.

Xarelto Expected to Increase Sales

Despite the fact that the drug companies have legal issues about another drug that has a controversial safety profile, Xarelto sales appears to be strong, and partners Bayer and J&J are making healthy profits. In the first year of the drug’s sales, Bayer generated about $431 million in Europe. J&J earned $239 million in U.S. sales.

Sales in both large markets continue to florish.

The drug follows in the footsteps of its predecessor, Boehringer Ingelheim’s Pradaxa, another drug that has vigourous sales. Even though the risk of internal bleeding concerned doctors, it did not appear to stop them from prescribing it.

Xarelto is currently approved for more uses than Pradaxa.

Bayer and J&J continue to pursue FDA approval despite being shut down for ACS treatment. The companies are investigating whether or not the drug can be used in combination with aspirin to stop heart attacks, death and stroke. In addition, the companies plan to start tests of Xarelto on patients with chronic artery disease and heart failure.

By 2018, analysts say Xarelto will generate about $3.68 billion in annual sales.

Why File a Xarelto Lawsuit?

 Approved in 2011, Xarelto (rivaroxaban) is one of the newest blood thinners on the market and is manufactured by Bayer and marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, in the United States. The most dangerous side effect for people taking Xarelto is uncontrollable bleeding �” a risk shared by all blood thinners. Some of the country’s top heart doctors are worried about Xarelto’s safety.

  • Financial suffering caused by emergency visits, long term care, and lost wages due to time away from work.
  • Emotional distress from taking care of loved ones experiencing medical problems
  • The burden of unexpected final expenses because of death as a result of uncontrolled bleeding caused by Xarelto.
  • Holding Bayer and Janssen Pharmaceuticals accountable for releasing a dangerous drug. Internal Bleeding

Multidistrict Litigation (MDL)

[weather city=”Streator” state=”Illinois”]

Because of the volume of lawsuits filed, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into multidistrict litigation (MDL). An MDL helps simplify the process because a number of cases can be handled by the same experienced judge and in the same court. People whose lawsuits are included in an MDL keep their own lawyers, and their suits are still handled as individual cases.

Where’s the exit strategy?
There is no such option for Xarelto. When a Xarelto Bleedout begins, there is little doctors can do to stop it.

The result can often lead to Xarelto Death.

Manufacturers of Xarelto and its competitors are hoping to find an antidote after the fact. For the time being, manufacturers are continuing to spend big dollars on new anticoagulants such as Xarelto, extolling the benefits of their efficacy and convenience.

[google-map location=”Streator IL”]

Instant SEO Plan
Rank on Page 1 of Google INSTANTLY!
45 E. Cityline Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: 484-881-3267

What class action lawsuit settlement options exist from the side effects of dosage of Risperdal medication in Piffard NY| Risperdal consta for depression, anxiety, bi-polar disorder and children in New York

[ssad ssadblk=”alta white”] You can assume there is a doctor in Piffard NY who has issued a prescription for Risperdal, just as there has been throught the country.
The Risperdal lawsuits list a range of side effects, including breast growth in men, an elevated risk of diabetes, heart disease and floppy iris syndrome for patients having cataract surgery. Since the drug usage is for patients young and old, people young and old have suffered through some of these side effects in different aspects.
In additional to these risks in adults, children may also be exposed to these side effects. Some recent reports identified antipsychotic drugs like Risperdal are becoming more popular as more doctors are prescribing them for off-label use.
[weather city=”Piffard” state=”New York”]
If you or someone you love has had an adverse effect or reaction from Risperdal, you may want to contact an experienced attorney who will be able to discern if you may have a case against J&J. For more information provide us with your contact information in the form below to see if we can help you.
[google-map location=”Piffard NY”]

 

J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts

 

[ssad ssadblk=”pain relief”]

 

Opening arguments made as case gets under way in Philadelphia

January 26, 2015 | By Eric Palmer

Johnson & Johnson ($JNJ) some time back agreed to pay $2.2 billion to settle federal claims that it improperly marketed the antipsychotic drug Risperdal. But the drugmaker’s legal hassles over the drug are not all done. Last week opening arguments were made in a case in which the drugmaker is accused of marketing the drug for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts.
In their opening arguments, lawyers for J&J’sJanssen countered that the FDA-approved label for the drug was sufficient because it lists the possibility of elevated levels of the hormone that can cause gynecomastia, the name for the condition.The case in the Philadelphia Court of Common Pleas revolves around a young man, now 20, that suffered that side effect, a condition his lawyers said in opening statements can only be dealt with through a mastectomy. According to a description of the opening arguments from Sheller, the law firm that brought the case, they contend their client was prescribed Risperdal “off label” at age 8. Former FDA Commissioner David Kessler is slated to testify in the case. He was brought to testify in some earlier cases but J&J then settled before they reached that point.

The drug, which went off patent in 2007, was a big seller for J&J. In the 7 years between 2003 to 2010, Risperdal brought in more than $24 billion worldwide. But the legal fallout from its off-label use has been costly to the drugmaker. In addition to the $2.2 billion settlement J&J made in the federal whistleblower lawsuit, it also settled off-label marketing claims with 36 states and the District of Columbia over the marketing of Risperdal that topped $180 million–then with Texas for $158 million more.

But it has also successfully fought off some verdicts. J&J lost a $1.2 billion verdict in Arkansas over similar claims but that mammoth award was killed last year when the Arkansas Supreme Court ruled that the state had filed the case under a statute that applied to healthcare companies but not pharma companies. J&J also deflected a $257 million award in Louisiana after convincing the supreme court in that state that its marketing had not violated a state law.

 

Instant SEO Plan
Rank On Page 1 of Google instantly.
45 E. City Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: (484) 881-3267

 

Find an attorney that handles Xarelto class action lawsuits in Alberta AL | Lawyers who makes claims settlements and litigation from Xarelto blood thinner in Alabama

[ssad ssadblk=”health plan “]

Blood thinner drug Xarelto, although having issues, continues to grow in sales.

 Pharmaceutical giants Bayer and Johnson & Johnson face the first lawsuits in response to safety concerns for the billion-dollar blood thinner Xarelto, according to Reuters.

Plaintiffs filed claims after severe internal bleeding had them end up in the hospital. In those cases, patients took Xarelto (rivaroxaban), and their claims blame the severe uncontrollable bleeding on that use.

Unlike warfarin, a trusted mainstay for preventing blood clots for the past 50 years, Xarelto has yet to have an antidote to stop uncontrolled bleeding, which can be fatal.

A patient from Kentucky Virginia Stunteneck filed a lawsuit against Bayer in the U.S. District Court of the Eastern District of Pennsylvania. Stunteneck was hospitalized after was given Xarelto and endured severe gastrointestinal bleeding in 2013.

She asserts the drug should be recalled and that J&J and Bayercontinued to sell it even if they knew the risks. The companies also did not disclose it to the public.

 

“As the manufacturers and distributors of Xarelto, defendants knew or should have known that Xarelto use was associated with irreversible bleeds,” Stunteneck’s complaint said.

In May, Boehringer Ingelheim paid $650 million to settle thousands of internal bleeding cases involving its blood thinner, Pradaxa. The drug hit the market in 2010, a year before Xarelto. Both drugs share the same bleeding side effects.

Attorneys say they expect more lawsuits after more people become aware of the potential hazards of the drug.  If you took Xarelto and had internal bleeding or a pulmonary embolism, you may have legal options.

[ssad ssadblk=”National Debt 3″]

 

GET HELP NOW

FDA Rejects Xarelto for Acute Coronary Syndrome

This initial group of claims comes soon after the U.S. Food and Drug Administration’s (FDA) advisory panel gave Xarelto a unanimous refusal for approval as a treatment for patients with sudden reduced blood flow to the heart, including heart attacks and chest pain, also known as acute coronary syndrome (ACS).

While the drug is approved for a number of uses, adding acceptance for ACS would grant Xarelto access to the 1.2 million Americans who find themselves going to the hospital each year with the condition.

The panel decision was a third strike for Bayer and J&J for FDA approval.

The panel voted that the drug should not be used to prevent new heart attacks and stroke in patients with ACS because there was not enough  clinical data to support the approval. The experts also indicated that some trial data was actually missing.

“We appreciate the thoroughness of the committee’s review and continue to believe rivaroxaban, in addition to the current standard of care, may help provide patients with ACS additional protection against life-threatening cardiovascular events such as death, heart attack and stroke,” Paul Burton, VP of clinical development for J&J’s Janssen R&D segment said in a statement.

Xarelto Expected to Increase Sales

Despite the fact that the drug companies have legal issues about another drug that has a questional safety profile, Xarelto sales appears to be strong, and partners Bayer and J&J are making healthy profits. In the first year of the drug’s sales, Bayer generated about $431 million in Europe. J&J earned $239 million in U.S. sales.

Sales in both large markets continue to florish.

The drug follows in the footsteps of its predecessor, Boehringer Ingelheim’s Pradaxa, another drug that has robust sales. Even though the risk of internal bleeding concerned doctors, it did not appear to stop them from prescribing it.

Xarelto is currently approved for more uses than Pradaxa.

Bayer and J&J continue to pursue FDA approval despite being shut down for ACS treatment. The companies are investigating whether or not the drug can be used in combination with aspirin to stop heart attacks, death and stroke. In addition, the companies plan to start tests of Xarelto on patients with chronic artery disease and heart failure.

By 2018, analysts say Xarelto will generate about $3.68 billion in annual sales.

Why File a Xarelto Lawsuit?

 Approved in 2011, Xarelto (rivaroxaban) is one of the newest blood thinners on the market and is manufactured by Bayer and marketed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, in the United States. The most damaging side effect for people taking Xarelto is uncontrollable bleeding �” a risk shared by all blood thinners. Some of the country’s top heart doctors are worried about Xarelto’s safety.

  • Financial suffering caused by emergency visits, ongoing care, and lost wages due to time away from work.
  • Emotional pain and suffering from taking care of loved ones experiencing medical problems
  • The burden of unexpected final expenses because of death as a result of uncontrolled bleeding caused by Xarelto.
  • Holding Bayer and Janssen Pharmaceuticals accountable for releasing a dangerous drug. Internal Bleeding

Multidistrict Litigation (MDL)

[weather city=”Alberta” state=”Alabama”]

Because of the large number of lawsuits filed, the U.S. Judicial Panel on Multidistrict Litigation consolidated these cases into multidistrict litigation (MDL). An MDL helps simplify the process because groups of cases can be handled by the same experienced judge and in the same court. People whose lawsuits are included in an MDL keep their own lawyers, and their suits are still handled [ndividually.

Where’s the exit strategy?
There is no such option for Xarelto. When a Xarelto Bleedout begins, there are so few options to stop it.

The result can many times lead to Xarelto Death.

Makers of Xarelto and its competitors are exploring options for an antidote after the fact. In the meantime, manufacturers are continuing to allocate huge budgets on new anticoagulants such as Xarelto, touting their effectiveness and convenience.

[google-map location=”Alberta AL”]

Instant SEO Plan
Rank on Page 1 of Google INSTANTLY!
45 E. Cityline Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: 484-881-3267

What class action lawsuit settlement options exist from the side effects of dosage of Risperdal medication in Villa Grove CO| Risperdal consta for depression, anxiety, bi-polar disorder and children in Colorado

[ssad ssadblk=”health plan “])

Risperdal doing more harm than good.

 

Risperdal is an antipsychotic treatment prescribed to patients with bipolar disorder and other behavioral problems.  The use of this drug has had many unexpected negative results for some people.

Risperdal was first approved by the Food and Drug Administration in 1993 to help reduce the effects of schizophrenia in adults. But since then, hundreds of lawsuits have been filed against the drug’s manufacturer, Johnson and Johnson, due to Risperdal side effects.  Cases have popped in many us cities as the drug has been widely distributed  It is likely there is a doctor in Villa Grove CO who has issued a prescription for Risperdal, just as there has been throught the country.

The Risperdal lawsuits list a range of side effects, including breast growth in males, an elevated risk of diabetes, heart disease and floppy iris syndrome for patients having cataract surgery.  Since the drug usage is for patients of all ages, people young and old have experienced some of these side effects in various levels.

In additional to these risks in adults, some children have been reported to experience some of these side effects. Some recent reports identified antipsychotic drugs like Risperdal are becoming more popular as more doctors are prescribing them for off-label use.

[weather city=”Villa Grove” state=”Colorado”]

If you or any of your family or friends has suffered harm from the use of Risperdal, you should find an experienced attorney who can determine if there are grounds to file a lawsuit against J&J. For more information provide us with your contact information in the form below to see if we can help you.

[google-map location=”Villa Grove CO”]

 

J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts

 

[ssad ssadblk=”asthma”]
Opening arguments made as case gets under way in Philadelphia

January 26, 2015 | By Eric Palmer

Johnson & Johnson ($JNJ) some time back agreed to pay $2.2 billion to settle federal claims that it improperly marketed the antipsychotic drug Risperdal. But the drugmaker’s legal hassles over the drug are not all done. Last week opening arguments were made in a case in which the drugmaker is accused of marketing the drug for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts.
In their opening arguments, lawyers for J&J’sJanssen countered that the FDA-approved label for the drug was sufficient because it lists the possibility of elevated levels of the hormone that can cause gynecomastia, the name for the condition.The case in the Philadelphia Court of Common Pleas revolves around a young man, now 20, that suffered that side effect, a condition his lawyers said in opening statements can only be dealt with through a mastectomy. According to a description of the opening arguments from Sheller, the law firm that brought the case, they contend their client was prescribed Risperdal “off label” at age 8. Former FDA Commissioner David Kessler is slated to testify in the case. He was brought to testify in some earlier cases but J&J then settled before they reached that point.

The drug, which went off patent in 2007, was a big seller for J&J. In the 7 years between 2003 to 2010, Risperdal brought in more than $24 billion worldwide. But the legal fallout from its off-label use has been costly to the drugmaker. In addition to the $2.2 billion settlement J&J made in the federal whistleblower lawsuit, it also settled off-label marketing claims with 36 states and the District of Columbia over the marketing of Risperdal that topped $180 million–then with Texas for $158 million more.

But it has also successfully fought off some verdicts. J&J lost a $1.2 billion verdict in Arkansas over similar claims but that mammoth award was killed last year when the Arkansas Supreme Court ruled that the state had filed the case under a statute that applied to healthcare companies but not pharma companies. J&J also deflected a $257 million award in Louisiana after convincing the supreme court in that state that its marketing had not violated a state law.

 

Instant SEO Plan
Rank On Page 1 of Google instantly.
45 E. City Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: (484) 881-3267

Your attorney in Warren MN to help with your transvaginal mesh implant surgery lawsuit | bad stress urinary incontinence SUI and pelvic sling and organ prolapsed procedures in Minnesota

[ssad ssadblk=”health plan “]

 

All You Want to Have Knowledge Of Transvaginal Mesh and so its Lawsuits

 

What could be Transvaginal Mesh?

Transvaginal mesh is a net-like plastic structure, which can be inserted in any woman through their vagina so as to overcome pelvic organ prolapsed (POP) coupled with stress urinary incontinence (SUI). “Transvaginal” is the name given to the distinctive approach applied to implant a transvaginal mesh in women’s body.

Pelvic organ prolapsed (POP) together with stress urinary incontinence (SUI) are disturbing issues many women experience shortly afterwards their menopause, childbirth and perhaps hysterectomy. In pelvic organ prolapsed (POP), a lot of women encounter weakening of their pelvic muscles as well as other pelvic parts inside the body such as anal cavity, bladder not to mention uterus.

Difficulties with Transvaginal Mesh

Implantation of transvaginal mesh may be accomplished through vagina and also stomach still surgeons want to insert it by the use of vagina since it is a lot more abrupt, practical and also much less intrusive. In spite of this, most of these procedures are not 100% trustworthy and safe and sound for females. Then there are additional complications suffered by ladies who have used effectively vaginal procedure for applying transvaginal mess into their body. Such as, women of all ages may encounter intense physical bacterial invasion, organ perforation combined with vaginal tissues start up eroding very quickly.

Mesh Erosion

Women suffer mesh corrosion once the embedded mesh goes on the vaginal wall or else starts out eroding alone inside the body. It is linked to unpleasant discomfort in the vaginal spot, extremely contaminated and light bleeding. In extreme predicaments, gals may also suffer nerve and skin harm.

Organ Perforation

It takes place immediately after mesh erosion whereby the transvaginal mesh could ruin several other bodily organs. The well-defined borders of transvaginal mesh trimed by itself out into physically organs which include bladder then trigger organ perforation. It happens to be linked to damaged internal organs all of which will need a special surgical procedures to protect against it from in depth possible damage.

[ssad ssadblk=”National Debt 1″]

Legal Factors Associated with Transvaginal Mesh Implantation

If you happen to be suffering from critical additional complications after transvaginal mesh implantation, you may even submit a personal injury suit against connected medical government agencies. According to the current essentials and numbers, there are actually 70,000 transvaginal mesh associated lawsuits of adult females are awaiting in West Virginia only.

Sensible Situations of Transvaginal Mesh Lawsuits

In 2013, Johnson & Johnson- Ethicon paid back $11 million to a woman for damages produced due to the sloppy surgery by organization healthcare authorities. Furthermore, the same business lost a personal injury suit against a woman and thus have been required to send her $1.2 million, as shown by ruling of Texas state courtroom.

C.R. Bard had been also prosecuted in July 2013 in the courtroom for providing disastrous transvaginal mesh service to a number of users. By February 2015, Bard appears to have been made to offer $250,000 as payment to the people who acquired the solutions and then later dealt with troubles.

In July 2013, American Medical Systems Inc. (AMS) paid back $54.4 million as pay to its suffering patients. Much the same, Boston scientific ended up being too ordered by the federal jury to forfeit $18.5 million in compensatory terms and $1 million in punitive terms to just 4 plaintiffs.

[ssad ssadblk=”free books”]

 

The correct way Individuals Lay Claim To Commissions?

Women, who report transvaginal mesh lawsuits, propose that healthcare government agencies have a lawful liability to assure protection and thus effectiveness of customized mesh items. Having encountered difficulties, it merely signifies that the government agencies released unreliable specifics about their products’ advantages. It is additionally believed that the medical-related government agencies did not actually warn them relating the barrier they can feel after the medical procedures which means that they should rightly be blamed as being frauds.

[weather city=”Warren” state=”Minnesota”]

Other females enter a lawsuit telling that transvaginal mesh appliances are purposefully deceiving FDA authorities as these products or services do not conform to the safety measures stipulations provided by the FDA. You do not have any conventional assessment or analysis process being utilized by the companies promoting transvaginal mesh goods, which could pretty much define dangers relevant to it.

[google-map location=”Warren MN”]

 

What class action lawsuit settlement options exist from the side effects of dosage of Risperdal medication in Elsmere NE| Risperdal consta for depression, anxiety, bi-polar disorder and children in Nebraska

[ssad ssadblk=”alta white”] It is very possible there is a doctor in Elsmere NE who has issued a prescription for Risperdal, just as there has been all across the country.
The Risperdal lawsuits list a host of side effects, including breast growth in men, an elevated risk of diabetes, heart disease and floppy iris syndrome for patients having cataract surgery. Since the drug usage is for patients of all ages, people young and old have suffered through some of these side effects in various levels.
On top of these risks in adults, some children have been reported to experience some of these side effects. Some recent reports identified antipsychotic drugs like Risperdal are becoming more popular as more doctors are prescribing them for off-label use.
[weather city=”Elsmere” state=”Nebraska”]
If you or someone you love has had an adverse effect or reaction from the use of Risperdal, you should find an experienced attorney who can determine if there are grounds to file a lawsuit against J&J. For more information fill out the form below to see if you may have a claim.
[google-map location=”Elsmere NE”]

 

J&J again faces off-label marketing claims in Risperdal case of boy who grew breasts

 

[ssad ssadblk=”pain relief”]

 

Opening arguments made as case gets under way in Philadelphia

January 26, 2015 | By Eric Palmer

Johnson & Johnson ($JNJ) some time back agreed to pay $2.2 billion to settle federal claims that it improperly marketed the antipsychotic drug Risperdal. But the drugmaker’s legal hassles over the drug are not all done. Last week opening arguments were made in a case in which the drugmaker is accused of marketing the drug for use in young boys and then not sufficiently warning patients that the side effects for some included the possibility they would grow breasts.
In their opening arguments, lawyers for J&J’sJanssen countered that the FDA-approved label for the drug was sufficient because it lists the possibility of elevated levels of the hormone that can cause gynecomastia, the name for the condition.The case in the Philadelphia Court of Common Pleas revolves around a young man, now 20, that suffered that side effect, a condition his lawyers said in opening statements can only be dealt with through a mastectomy. According to a description of the opening arguments from Sheller, the law firm that brought the case, they contend their client was prescribed Risperdal “off label” at age 8. Former FDA Commissioner David Kessler is slated to testify in the case. He was brought to testify in some earlier cases but J&J then settled before they reached that point.

The drug, which went off patent in 2007, was a big seller for J&J. In the 7 years between 2003 to 2010, Risperdal brought in more than $24 billion worldwide. But the legal fallout from its off-label use has been costly to the drugmaker. In addition to the $2.2 billion settlement J&J made in the federal whistleblower lawsuit, it also settled off-label marketing claims with 36 states and the District of Columbia over the marketing of Risperdal that topped $180 million–then with Texas for $158 million more.

But it has also successfully fought off some verdicts. J&J lost a $1.2 billion verdict in Arkansas over similar claims but that mammoth award was killed last year when the Arkansas Supreme Court ruled that the state had filed the case under a statute that applied to healthcare companies but not pharma companies. J&J also deflected a $257 million award in Louisiana after convincing the supreme court in that state that its marketing had not violated a state law.

 

Instant SEO Plan
Rank On Page 1 of Google instantly.
45 E. City Ave, Suite 526
Bala Cynwyd, PA
19004
US
Phone: (484) 881-3267